The drug is used to treat bacterial vaginosis and is a generic version of Bausch Health US LLC’s MetroGel-Vaginal.
The US Food & Drug Administration (FDA) granted final approval to Glenmark Pharmaceuticals (Glenmark) on Friday for its metronidazole topical gel as a generic version of Bausch Health US LLC’s MetroGel-Vaginal.1
According to IQVIA sales data for the 12-month period ending in November 2021, MetroGel-Vaginal reported annual sales of approximately $60.4 million.
The global pharmaceutical company’s key therapeutic areas of focus include respiratory, dermatology, and oncology.
Glenmark’s new product adds to the firm’s growing portfolio of 173 products authorized for US distribution, with an additional 46 abbreviated new drug applications pending FDA approval.
Reference
Tocolysis use after PPROM not linked to neurodevelopmental outcomes
May 29th 2024A recent study investigated the effects of antenatal tocolysis on neurodevelopmental outcomes among children aged 5.5 years following preterm prelabor rupture of membranes, revealing no significant differences in outcomes.
Read More
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
Study finds youth with developmental disabilities less likely to access reproductive health care
May 22nd 2024A recent study reveals that adolescents with autism and other developmental disabilities have fewer visits to obstetrician-gynecologists and lower hormonal contraceptive use compared to their typically developing peers, highlighting a need for improved reproductive health services.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Rising endometriosis rates linked to increased pregnancy complications
May 19th 2024A new study presented at the 2024 ACOG meeting reveals a significant rise in endometriosis among pregnant women over the past 20 years, linking the condition to increased obstetric and neonatal complications.
Read More